NCT06132958: TroFuse-005

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Active, enrolled Phase 3 Last updated 3 April 2026

What this trial tests

Phase 3 trial testing Sacituzumab tirumotecan in Endometrial Cancer in 710 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

6 December 2023

Primary endpoint
10 January 2028

10 January 2028

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	710
Start date	6 December 2023
Primary completion	10 January 2028
Estimated completion	10 January 2028
Sites	241 locations across Italy, Finland, Japan, Malaysia, Ireland, Poland, South Korea, Denmark

Drugs / interventions tested

• Sacituzumab tirumotecan
• Doxorubicin (doxorubicin) — full drug profile →
• Paclitaxel — full drug profile →
• Nab-paclitaxel (nab-paclitaxel) — full drug profile →
• Rescue medications

Conditions studied

• Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.
   Wang R, Hu B, Pan Z, Mo C, et al · · 2025 · cited 105× · PMID 40307936 · DOI 10.1186/s13045-025-01704-3
2. Antibodies to watch in 2025.
   Crescioli S, Kaplon H, Wang L, Visweswaraiah J, et al · · 2025 · cited 87× · PMID 39711140 · DOI 10.1080/19420862.2024.2443538
3. Advancements in antibody-drug conjugates as cancer therapeutics.
   Fong JY, Phuna Z, Chong DY, Heryanto CM, et al · · 2025 · cited 11× · PMID 40814440 · DOI 10.1016/j.jncc.2025.01.007
4. Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment.
   Albertí-Valls M, Olave S, Olomí A, Macià A, et al · · 2024 · cited 11× · PMID 39682106 · DOI 10.3390/cancers16233918
5. Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025.
   Silverstein J, Karlan B, Herrington N, Konecny G. · · 2025 · cited 11× · PMID 39480912 · DOI 10.1097/gco.0000000000001002
6. Future AI Will Most Likely Predict Antibody-Drug Conjugate Response in Oncology: A Review and Expert Opinion.
   Sobhani N, D'Angelo A, Pittacolo M, Mondani G, et al · · 2024 · cited 10× · PMID 39272947 · DOI 10.3390/cancers16173089
7. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.
   Chen B, Zheng X, Wu J, Chen G, et al · · 2025 · cited 4× · PMID 41184856 · DOI 10.1186/s12943-025-02489-2
8. Drug discovery in advanced and recurrent endometrial cancer: Recent advances.
   Francoeur AA, Ayoub N, Greenberg D, Tewari KS. · · 2025 · cited 4× · PMID 40612873 · DOI 10.32604/or.2025.061120